Pulmonary complications after Fluosol administration to patients with life-threatening blood loss.
Fluosol-DA 20% (Fluosol), a perfluorochemical emulsion capable of improving oxygen transport, was used to treat three patients with life-threatening hemorrhage. In each case a decreased partial pressure of oxygen, an increased alveolar-arterial oxygen gradient, fever, an increased white blood cell count, and chest x-ray abnormalities occurred at similar time intervals after treatment with Fluosol. In one patient, pulmonary complications were fatal. Similar adverse reactions to treatment with Fluosol have not been previously reported. Possible explanations for these pulmonary complications are the adult respiratory distress syndrome, oxygen toxicity, or direct toxic effects of Fluosol.
D000328:Adult; D000368:Aged; D001802:Blood Substitutes / Q000009:adverse effects*; D002835:Christianity; D004338:Drug Combinations / Q000009:adverse effects; D005260:Female; D005466:Fluorocarbons / Q000009:adverse effects*; D006470:Hemorrhage / Q000150:complications / Q000628:therapy*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D010100:Oxygen / Q000502:physiology; D012128:Respiratory Distress Syndrome / Q000139:chemically induced
D001802:Blood Substitutes; D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen